Astellas Pharma (Astellas Pharma) Total Stockholders Equity : $10,441 Mil (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Total Stockholders Equity?

Astellas Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $10,441 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Astellas Pharma's Book Value per Share for the quarter that ended in Dec. 2023 was $5.82. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Astellas Pharma's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.58.

Astellas Pharma Total Stockholders Equity Historical Data

The historical data trend for Astellas Pharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Total Stockholders Equity Chart

Astellas Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Stockholders Equity

Get a 7-Day Free Trial

11,322.18

11,973.63

12,751.85

12,315.23

11,281.65

Astellas Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															11,640.12	11,281.65	11,166.09	11,088.27	10,440.61

Astellas Pharma (OTCPK:ALPMY) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Astellas Pharma's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(10440.612	-	0)	/	1792.99
	=	5.82

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Astellas Pharma's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2827.981	+	3221.275)	/	10440.612
	=	0.58

Astellas Pharma Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma (Astellas Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ALPMF:USA 4503:Mexico 4503:Japan YPHA:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.